+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rheumatoid Arthritis Drug"

From
Rheumatoid Arthritis Drugs Market Report 2025 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
From
From
Juvenile Rheumatoid Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Juvenile Rheumatoid Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
JAK Inhibitors Market - Product Thumbnail Image

JAK Inhibitors Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Autoimmune Drugs Market 2024-2028 - Product Thumbnail Image

Autoimmune Drugs Market 2024-2028

  • Report
  • July 2024
  • 185 Pages
  • Global
From
Loading Indicator

The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain. The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more